Newsbenzinga
AIM ImmunoTech Announces USPTO Granted Patent Covering Use Of Ampligen In Combination With Pembrolizumab For Cancer Treatment, Expiring December 20, 2039
· Published
Article summary
Please check the source for details.
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…